1 in 5 people may carry this hidden genetic heart risk
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Researchers analyzed stored plasma samples from 20,070 participants aged 40+ in the NIH's ACCORD, PEACE, and SPRINT trials, finding that Lp(a) levels ≥175 nmo/L were independently associated with a 31% higher risk of major adverse cardiovascular events (HR 1.31, 95% CI: 1.10–1.55).
- High Lp(a) at the same threshold was linked to a 49% greater risk of cardiovascular death (HR 1.49) and a 64% greater risk of stroke (HR 1.64), but was NOT associated with higher heart attack risk.
- Lp(a) is a cholesterol-carrying particle that resembles LDL but carries an extra protein making it more atherogenic; roughly 1 in 5 people has elevated levels, almost always without symptoms, because standard cholesterol panels do not measure it.
- The association was stronger in patients who already had heart disease (HR 1.30) than in those without prior cardiovascular disease (HR 1.18), suggesting Lp(a) adds incremental risk on top of existing conditions.
- Lead author Subhash Banerjee, MD, an interventional cardiologist at Baylor Scott & White in Dallas, said the findings let clinicians 'quantify the specific level of Lp(a)' that confers elevated risk and urged patients to use a 'simple, low-cost blood test' if Lp(a) comes back high.
- The findings were presented as late-breaking science at the SCAI 2026 Scientific Sessions and CAIC-ACCI Summit in Montreal; researchers plan follow-up analyses in chronic kidney disease and peripheral artery disease populations.
- Stored biospecimens from already-completed randomized trials were reanalyzed using a standardized assay, a method the authors said can extract new risk-prediction insights from existing trials without new enrollment.
Why it matters: Roughly 20% of adults carry elevated Lp(a) without knowing it because the particle is invisible to standard lipid panels, and the study now pins a specific actionable cutoff (≥175 nmo/L) tied to a 64% jump in stroke risk. For the 31% of high-Lp(a) patients who already have heart disease, the incremental hazard is even larger — giving clinicians a concrete case to screen and to push LDL and other modifiable risk factors harder while targeted Lp(a) therapies remain in development.
Ask SkimNews
